Skip to main content

Cavanaugh Sarah's Form 4 filing

Celldex Therapeutics, Inc. (CLDX) · filed Nov 3, 2021

Accession no.
0001179110-21-009818
Filed
Nov 3, 2021
Trade date
Nov 1, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $316.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cavanaugh SarahCIK 0001709113Officer (SVP of Corp Affairs & Admin.)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 1, 2021Common StockMOption exerciseAcquired+5,018$9.02+$45,262.366,793Direct
Nov 1, 2021Common StockMOption exerciseAcquired+938$2.78+$2,607.647,731Direct
Nov 1, 2021Common StockSSaleDisposed−4,302$44.11−$189,761.223,429Direct
Nov 1, 2021Common StockSSaleDisposed−901$43.06−$38,797.062,528Direct
Nov 1, 2021Common StockSSaleDisposed−2,120$41.62−$88,234.4408Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 1, 2021Common StockMOption exerciseDisposed−5,018$0.00$013,315Direct
Nov 1, 2021Common StockMOption exerciseDisposed−938$0.00$042,062Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)